Gallien, Sébastien <br/><br/>
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.  [electronic resource] 

 -  The Journal of antimicrobial chemotherapy  Sep 2011 
 - 2099-106 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1460-2091 
<br/><br/><label>Standard No.: </label>10.1093/jac/dkr269  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alanine Transaminase--blood<br/>CD4 Lymphocyte Count<br/>Drug Resistance, Multiple, Viral<br/>Endpoint Determination<br/>Enfuvirtide<br/>Female<br/>France<br/>Genotype<br/>HIV Envelope Protein gp41--therapeutic use<br/>HIV Fusion Inhibitors<br/>HIV Infections--blood<br/>HIV Integrase Inhibitors--adverse effects<br/>HIV-1<br/>Humans<br/>Male<br/>Microbial Sensitivity Tests<br/>Middle Aged<br/>Peptide Fragments--therapeutic use<br/>Pilot Projects<br/>Prospective Studies<br/>Pyrrolidinones--adverse effects<br/>RNA, Viral--blood<br/>Raltegravir Potassium<br/>Treatment Outcome